

25. Rudi J, Kolb C, Maiwald M, et al. Diversity of *Helicobacter pylori vacA* and *cagA* genes and relationship to VacA and CagA protein expression, cytotoxin production, and associated diseases. *J Clin Microbiol*. 1998;36:944-948.
26. De Re V, De Vita S, Carbone A, et al. The relevance of VDJ PCR protocols in detecting B-cell clonal expansion in lymphoma and other lymphoproliferative disorders. *Tumori*. 1995;81:405-409.
27. Trainor KJ, Brisco MJ, Wan JH, Neoh S, Grist S, Morley AA. Gene rearrangement in B- and T-lymphoproliferative disease detected by polymerase chain reaction. *Blood*. 1991;78:192-196.
28. Nam S-H, Kim B-S, Lee JH, et al. The clinical efficacy of *Helicobacter pylori* eradication in patients with *Helicobacter pylori*-positive chronic thrombocytopenic purpura [abstract]. *Blood*. 2005;106:80b. Abstract no. 4002.
29. Jang JH, Kim HI, Lee HW, et al. Correlation between *Helicobacter pylori* eradication and platelet count in immune thrombocytopenic purpura (ITP) [abstract]. *Blood*. 2005;106:80b. Abstract no. 4003.
30. Jaing TH, Yang CP, Hung IJ, Chin CH, Chang KW. Efficacy of *Helicobacter pylori* eradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura. *Acta Paediatr*. 2003;92:1153-1157.
31. Neeffjes VME, Heijboer H, Tamminga RYJ. *H. pylori* infection in childhood chronic immune thrombocytopenic purpura. *Haematologica*. 2007;92:576.
32. Michel M, Cooper N, Jean C, Frizzera C, Bussel JB. Does *Helicobacter pylori* initiate or perpetuate immune thrombocytopenic purpura? *Blood*. 2004;103:890-896.
33. Ahn ER, Tiede MP, Jy W, Bidot CJ, Fontana V, Ahn YS. Platelet activation in *Helicobacter pylori*-associated idiopathic thrombocytopenic purpura: eradication reduces platelet activation but seldom improves platelet counts. *Acta Haematol*. 2006;116:19-24.
34. Jarque I, Andreu R, Llopis I, et al. Absence of platelet response after eradication of *Helicobacter pylori* infection in patients with chronic idiopathic thrombocytopenic purpura. *Br J Haematol*. 2001;115:1002-1003.
35. Garcia-Perez A, Valverde de la Osa J, Gimenez Samper M, Alonso Garcia I. Resolution of an autoimmune thrombocytopenic purpura after eradicating treatment of *Helicobacter pylori*. *Sangre (Barcelona)*. 1999;44:387-388.
36. Dominici P, Bellentani S, Di Biase AR, et al. Familial clustering of *Helicobacter pylori* infection: population based study. *BMJ*. 1999;319:537-540.
37. Russo A, Eboli M, Pizzetti P, et al. Determinants of *Helicobacter pylori* seroprevalence among Italian blood donors. *Eur J Gastroenterol Hepatol*. 1999;11:867-873.
38. Franchini M, Veneri D. *Helicobacter pylori* infection and immune thrombocytopenic purpura: an update. *Helicobacter*. 2004;9:342-346.
39. Michel M, Khellaf M, Desforges L, et al. Autoimmune thrombocytopenic purpura and *Helicobacter pylori* infection. *Arch Intern Med*. 2002;162:1033-1036.
40. Ando T, Tsuzuki T, Mizuno T, et al. Characteristics of *Helicobacter pylori*-induced gastritis and the effect of *H. pylori* eradication in patients with chronic idiopathic thrombocytopenic purpura. *Helicobacter*. 2004;9:443-452.
41. Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by *Helicobacter pylori* CagA protein may be involved in the pathogenesis of *H. pylori*-associated chronic idiopathic thrombocytopenic purpura. *Br J Haematol*. 2004;124:91-96.
42. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. *Ann Intern Med*. 2007;146:25-33.
43. Ohguchi H, Kameoka J, Harigae H, et al. Can the *Helicobacter pylori* eradication regimen induce platelet recovery in *H. pylori*-negative patients with idiopathic thrombocytopenic purpura? *Am J Hematol*. 2005;78:164-165.
44. Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. *J Immunol*. 2002;168:3675-3682.
45. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. *Nat Med*. 2003;9:1123-1124.
46. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. *Blood*. 2004;103:1364-1369.
47. Shimoyama T, Crabtree JE. Bacterial factors and immune pathogenesis in *Helicobacter pylori* infection. *Gut*. 1998;43:52-55.
48. Veneri D, Gottardi M, Guizzardi E, Zanuso C, Krampera M, Franchini D. Idiopathic thrombocytopenic purpura, *Helicobacter pylori* infection, and HLA class II alleles. *Blood*. 2002;100:1925-1926.
49. Takahashi T, Yujiri T, Tanizawa T. *Helicobacter pylori* and chronic ITP: the discrepancy in the clinical responses to eradication therapy might be due to differences in the bacterial strains. *Blood*. 2004;104:594.
50. Byrne MF, Kerrigan SW, Corcoran PA, et al. *Helicobacter pylori* binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. *Gastroenterology*. 2003;124:1846-1854.
51. Kraft M, Tiemann M, Riedel S, et al. Compartment analysis of T cell receptor gamma-and immunoglobulin V (H) rearrangements by microdissection in patients with malt lymphoma and chronic gastritis with lymphatic hyperplasia. *Cell Mol Biol (Noisy-le-grand)*. 2002;48:253-263.
52. Georgopoulos SD, Triantafyllou K, Fameli M, et al. Molecular analysis of B-cell clonality in *Helicobacter pylori* gastritis. *Digest Dis Sci*. 2005;50:1616-1620.
53. Veneri D, De Matteis G, Solero P, et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with *Helicobacter pylori* infection and response to eradication treatment. *Platelets*. 2005;16:307-311.
54. Ishiyama M, Teramura M, Iwabe K, Kato T, Motoji T. Clonally expanded T-cells in the peripheral blood of patients with idiopathic thrombocytopenic purpura and *Helicobacter pylori* infection. *Int J Haematol*. 2006;83:147-151.
55. Kim J, Park CJ, Chi HS, et al. Idiopathic thrombocytopenic purpura: better therapeutic responses of patients with B- or T-cell clonality than patients without clonality. *Int J Haematol*. 2003;78:461-466.
56. Zambon CF, Navaglia F, Basso D, Rugge M, Plebani M. *Helicobacter pylori babA2*, *cagA*, and *S1 vacA* genes work synergistically in causing intestinal metaplasia. *J Clin Pathol*. 2003;56:287-291.
57. Yamaoka Y, Kodama T, Gutierrez O, et al. Relationship between *Helicobacter pylori iceA*, *cagA*, and *vacA* status and clinical outcome: studies in four different countries. *J Clin Microbiol*. 1999;37:2274-2279.

Erratum

In the article by Zhang et al entitled "Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo," which appeared in the July 1, 2007, issue of *Blood* (Volume 110:228-236), 2 panels in Figure 2 were switched. The panel labeled D should have been panel E, and the panel labeled E should have been panel D.